Use of lipoprotein(a) for refining cardiovascular risk prediction in a low-risk population: The CoLaus/PsyCoLaus study
Eur J Prev Cardiol
.
2021 Jul 23;28(8):e18-e20.
doi: 10.1177/2047487320938271.
Epub 2020 Jul 5.
Authors
Benoît Delabays
1
,
Pedro Marques-Vidal
1
2
,
Florian Kronenberg
3
,
Gérard Waeber
1
2
,
Peter Vollenweider
1
2
,
Julien Vaucher
1
2
Affiliations
1
Department of Medicine, Lausanne University Hospital and University of Lausanne, Switzerland.
2
Faculty of Biology and Medicine, University of Lausanne, Switzerland.
3
Institute of Genetic Epidemiology, Medical University of Innsbruck, Austria.
PMID:
34298560
DOI:
10.1177/2047487320938271
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Cardiovascular Diseases* / diagnosis
Cardiovascular Diseases* / epidemiology
Heart Disease Risk Factors
Humans
Lipoprotein(a)*
Risk Factors
Switzerland
Substances
Lipoprotein(a)